FTRE · Fortrea Holdings Inc.
$17.73
-0.03 (-0.17%)
At close · Jul 20
Market Cap
$1.68B
Shares
94.60M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.73
Open$17.64
Day$17.49–17.84
52W$4.46–18.67
Avg vol 30d1.2M
Short int9.8M · 10.3% float · 5.3d
Short vol51%
Last earningsJul 29, 2026
DataJun 2023–Jul 2026
Filing10-Q · May 5
Up next
Next earnings call
Jul 29, 2026
Scheduled
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+34%
above
Price vs 50-day avg
+10%
above
RSI (14)
59
neutral
MACD trend
Negative
52-week position
93%
near high
Momentum
relative strength
1-month return
+16%
trailing
6-month return
+4%
trailing
YTD return
+3%
this year
Relative strength
−3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
47 of 331 funds reported for Jun 30 · net +206.3K sh shares · +5 new
Insider flow
Distributing
Net -$256.2K over 90 days · 100% sells
Short interest
Falling
10.33% of float · ▼ -0.9% MoM · 5.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
331 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+1%
Y/Y
EPS growth
−195%
Y/Y
Balance sheet
$878.2M
net debt
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 5, 2026
Adjusted EBITDA
· full year 2026
Non-GAAP
Initiated
$190M – $220M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+34%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
59
Neutral
MACD trend
Negative
Bearish
52-week position
93%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $16 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
47 of 331 funds reported for Jun 30 · net +206.3K sh shares · +5 new
Insider flow
Distributing
Net -$256.2K over 90 days · 100% sells
Short interest
Falling
10.33% of float · ▼ -0.9% MoM · 5.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
331 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $4
Now $18 · 93%
52-wk high $19
vs 200-day avg +34%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net income non-GAAP | $15.2M | Q1 2026 | — |
| Backlog | $7,846M | as of March 31, 2026 | — |
| Book-to-bill ratio | 1.15 | Q1 2026 | — |
|
|
|||
| Trailing 12 months book-to-bill | 1.05 | Q1 2026 | — |
| Q1 book-to-bill | 1.15 | Q1 FY2026 call | — |
| Free cash flow | $88.3M | the full year | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FTRE
this stock
Fortrea Holdings Inc.
|
$1.68B | +2.8% | +1.0% | — | 10.3% |
|
ONC
BeOne Medicines Ltd.
|
$448.86B | +2.2% | +22179.2% | 913.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.95B | +6.0% | +46.2% | 28.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.47B | -12.8% | +20.8% | 16.4 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +0.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FTRE | -0.7% | +15.8% | +3.9% | +1.9% | +2.8% |
| SPY | -1.0% | -0.6% | +7.1% | -0.6% | +8.8% |
| vs SPY | +0.2% | +16.4% | -3.2% | +2.5% | -6.0% |
Key facts
CIK
1965040
CUSIP
34965K107
13F (30d)
47 filings
46 filers
Visit website
Investor relations